Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125631111 | 12563111 | 1 | I | 20160529 | 20160712 | 20160715 | 20160715 | EXP | IT-MINISAL02-366746 | IT-MYLANLABS-2016M1029252 | MYLAN | 0.00 | Y | 0.00000 | 20160715 | MD | IT | IT |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125631111 | 12563111 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 280 MG TOTAL | 77042 | 280 | MG | TABLET | |||||||
125631111 | 12563111 | 2 | SS | TAVOR (LORAZEPAM) | LORAZEPAM | 1 | Oral | 20 DF TOTAL | 0 | 20 | DF | TABLET |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125631111 | 12563111 | 1 | Product used for unknown indication |
125631111 | 12563111 | 2 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125631111 | 12563111 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125631111 | 12563111 | Drug abuse | |
125631111 | 12563111 | Intentional overdose | |
125631111 | 12563111 | Sopor | |
125631111 | 12563111 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125631111 | 12563111 | 1 | 20160529 | 20160529 | 0 | |
125631111 | 12563111 | 2 | 20160529 | 20160529 | 0 |